> Intravenous Immunoglobulin (IVIG) — Mechanism, Trials &

← All agents | ← Research tracker

Intravenous Immunoglobulin (IVIG)

Also known as: Intravenous Immunoglobulin (IVIG)

PubChem entry

Evidence Summary

Evidence Level: Moderate
Mechanism: Anti-inflammatory, Enrollment: Actual, Immunomodulatory, Neurological / Autonomic
Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing: See linked studies/trials for reported doses and durations; typical protocols vary widely.
Investigational for listed conditions. 2 associated trial(s) and 5 study reference(s) in current data. Review primary sources and consult specialists before use.

Related Conditions

Long COVID (no page yet) · Lyme (no page yet) · ME/CFS (no page yet) · Other Post-Viral (Post-infectious cough, Q-fever fatigue syndrome, Post-dengue fatigue, Chikungunya post-infectious, Parvovirus B19 GBS, Mycoplasma pneumoniae neurological, Herpes encephalitis sequelae, RIME, etc.) (no page yet) · POTS (no page yet)

Clinical Trials

2 trial(s) registered

NCT06305793: RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG) PHASE2 ACTIVE_NOT_RECRUITING
NCT06305780: RECOVER-AUTONOMIC Platform Protocol PHASE2 COMPLETED

Key Studies / References